Development of a Scalable Synthesis of Mevidalen (LY3154207) an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor PDF807 KB
Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 ReceptorRichardson · Organic Process Research & Development2020PDF440 KB
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson DiseaseWilbraham · Clinical Pharmacology in Drug Development2022PDF1.2 MB
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy SubjectsWilbraham · Clinical Pharmacology in Drug Development2020PDF1.6 MB
The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male VolunteersMcCarthy · American Society for Pharmacology & Experimental Therapeutics (ASPET)2021PDF1.3 MB